Today: February 16, 2019 9:04 am
Location Kit

Tag: Clinical trials and medical discoveries


MEI Pharma presents preclinical information demonstrating that Voruciclib synergistically induces apoptosis together with venetoclax in acute myeloid leukemia cells on the annual assembly of the American Society of Hematology 2018
December 2, 2018

MEI Pharma presents preclinical information demonstrating that Voruciclib synergistically induces apoptosis together with venetoclax in acute myeloid leukemia cells on the annual assembly of the American Society of Hematology 2018

SAN DIEGO, December 1, 2018 / PRNewswire / – MEI Pharma, Inc. (NASDAQ: MEIP), an advanced-stage pharmaceutical firm targeted on advancing new therapies for most cancers, right now introduced preclinical information offered on the annual assembly of the American Society of Hematology (ASH). ) from 2018 demonstrating that voruciclib Inhibited, clinically induced CDK9 inhibitor, synergistically induced apoptosis at clinically related concentrations when mixed with venetoclax (marketed as Venclexta®) in human derived acute myeloid leukemia (AML) traces and affected person samples. Voruciclib is at present being evaluated in a Part. 1 B Dose...

Continue Reading
Share
A Washington court approves a $ 14.25 million class action settlement for women who used a religious bath where the Georgetown rabbi made secret registrations
October 28, 2018

The 2-year knowledge for Novartis brolucizumab reaffirm the prevalence to aflibercept in fluid discount in sufferers with DMN

HANOVER DEL ESTE, N.J., October 27, 2018 / PRNewswire / – Novartis declares further outcomes of second section brolucizumab Part III that reaffirmed optimistic first 12 months outcomes. Brolucizumab places its main endpoint of noninferiority to aflibercept in one of the best corrected visible acuity (MCVA) and confirmed a superiority in the important thing retinal ends in one (48 weeks)1.2. The secondary endpoints in two years (96 weeks) reaffirmed the prevalence of brolucizumab 6 mg within the discount of retinal fluid, an vital marker of illness exercise in sufferers with age-related macular...

Continue Reading
Share